Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) — Ascendis…
#Europe #EU #(Navepegritide) #10 #approval #CNP #European #EuropeanUnion #Exclusivity #in #market #of #Once-Weekly #Receive #the #to #TransCon® #Union #Upon #years
https://www.europesays.com/europe/175801/